Leukemia Clinical Trials in Baltimore

Showing 601-620 of 899 trials

An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

NCT02783651

A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.

Relapsed/Refractory Acute Lymphoblastic Leukemia

Amgen212 participantsStarted Jun 2016

Tucson, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +16 more locations

COMPLETEDPHASE3< 1 mile

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

NCT01829711

Background: \- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase III multicenter trial designed to confirm these results.

Leukemia, Hairy Cell

MedImmune LLC80 participantsStarted Apr 2013

Duarte, California, United States • Los Angeles, California, United States • Miami, Florida, United States +31 more locations

An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Leukemia Trials in Other Cities

Analyses of Human Samples Collected in Clinical Trials

Improving Balance and Mobility

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies

Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers

Preventing Falls Among Older Fallers to Test the Effect of LIVE-LiFE, a Home-Based, Tailored Fall Prevention Program

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Study Comparing OsseoSpeed™ Implants of Two Different Lengths in the Upper and Lower Posterior Jaw

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Other Conditions in Baltimore